a. mAbs is a multidisciplinary, peer-reviewed, open access journal dedicated to the art and science of antibody research and development. b. Dr. Pushpa Narayanaswami has provided consulting ...

It can be effectively treated with both mAbs and antivirals ... publishing their findings in the New England Journal of Medicine. They discovered that imdevimab, casirivimab, tixagevimab ...

The new guidelines for the use of monoclonal antibodies (mAbs) published in Neurodegenerative Diseases, serve as exemplary clinical recommendations for clinicians and healthcare providers, supporting ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics ... with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled “The anti-GD2 ...

They are a type of medical treatment. Scientists make monoclonal antibodies, or mAbs, in a lab. They work like the natural antibodies your body makes to fight illness. They go out into your body ...

Y-mAbs Therapeutics YMAB stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete Response ...